A PHASE 11, RANDOMIZED, DOUBLE-BLÍND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, WORLDWIDE, DOSE-RANGING CLÍNICAL TRIAL WITH A PROOF-OF-CONCEPT LEAD COHORT TO EVALUATE THE SAFETY, TOLERABILITY, ...
Update Il y a 4 ans
Reference: PER-036-12
A PHASE 11, RANDOMIZED, DOUBLE-BLÍND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, WORLDWIDE, DOSE-RANGING CLÍNICAL TRIAL WITH A PROOF-OF-CONCEPT LEAD COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF MK-8457 + MTX IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
